darolutamide
Selected indexed studies
- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (N Engl J Med, 2022) [PMID:35179323]
- Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. (J Clin Oncol, 2024) [PMID:39279580]
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. (N Engl J Med, 2019) [PMID:30763142]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study. (2024) pubmed
- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (2022) pubmed
- Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. (2024) pubmed
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. (2019) pubmed
- Darolutamide. (2012) pubmed
- Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. (2023) pubmed
- Darolutamide: First Approval. (2019) pubmed
- Darolutamide-mediated phospholipid remodeling induces ferroptosis through the SREBP1-FASN axis in prostate cancer. (2024) pubmed
- Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC. (2025) pubmed
- Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer. (2023) pubmed